Transdermal Rivastigmine

Greenspoon, Jill; Herrmann, Nathan; Adam, David N.
July 2011
CNS Drugs;2011, Vol. 25 Issue 7, p575
Academic Journal
Alzheimer's disease is a chronic neurodegenerative disorder resulting in part from the degeneration of cholinergic neurons in the brain. Rivastigmine, a cholinesterase inhibitor, is commonly used as a treatment for dementia due to its ability to moderate cholinergic neurotransmission; however, treatment with oral rivastigmine can lead to gastrointestinal adverse effects such as nausea and vomiting. Transdermal administration of rivastigmine can minimize these adverse effects by providing continuous delivery of the medication, while maintaining the effectiveness of the oral treatment. While the transdermal form of rivastigmine has been found to have fewer systemic adverse effects compared with the oral form, cutaneous reactions, such as contact dermatitis, can lead to discontinuation of the drug in its transdermal form. Lack of patient compliance with regard to applying the patch to the designated site, applying the patch for the correct length of time or rotating patch application sites increases the risk of cutaneous adverse reactions. This article outlines the diagnosis and management of irritant contact dermatitis and allergic contact dermatitis secondary to transdermal rivastigmine. The large majority of reactions to transdermal patches are of an irritant type, which can be diagnosed clinically by the presence of a pruritic, erythematous, eczematous plaque strictly confined to the borders of the patch. In contrast, an allergic reaction can be differentiated by the presence of vesicles and/or oedema, erythema beyond the boundaries of the transdermal patch and lack of improvement of the lesion 48 hours after removal of the offending treatment. By encouraging the patient to follow a regular rotation schedule for the patch, and using lipid-based emollients for irritant dermatitis and pre- and post-treatment topical corticosteroids for allergic dermatitis, cutaneous reactions can often be alleviated and patients can continue with their medication regimen. Other simple changes to a patient's treatment routine, including minimizing the use of harsh soaps, avoiding recently shaven or damaged areas of skin and carefully removing the patch after use, can help to further decrease the risk of dermatitis development.


Related Articles

  • Rivastigmine Transdermal Patch: A Review of its Use in the Management of Dementia of the Alzheimer's Type. Dhillon, Sohita // Drugs;2011, Vol. 71 Issue 9, p1209 

    Rivastigmine, a cholinesterase inhibitor, is available as a transdermal patch (Exelon® patch, Rivastach® patch, Prometax® patch) for the treatment of mild to moderate Alzheimer's disease. Rivastigmine transdermal patch was effective, in terms of improving cognitive and global function,...

  • Acetylcholine and memory-enhancing activity of Ficus racemosa bark. Ahmed, Faiyaz; Chandra, J. N. Narendra Sharath; Manjunath, S. // Pharmacognosy Research;Oct2011, Vol. 3 Issue 4, p246 

    Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and enhancement of acetylcholine (Ach) levels in brain using acetylcholinesterase inhibitors is one of the most important approaches for the treatment of AD. Methods: In this study, aqueous...

  • THE EFFICIENCY OF ADMINISTERING DRUGS TROUGH TRANSDERMIC SYSTEMS. DUKA, Robert; MUNTEANU, Melania // Studia Universitatis Vasile Goldis Seria Stiintele Vietii (Life ;2012, Vol. 22 Issue 4, p537 

    Transdermal delivery systems have become more increasingly important for treating neurologic and psychiatric disorders. Cholinesterase inhibitors have all been available in oral formulations but the rivastigmine patch was the first patch to be approved to treat Alzheimer's disease (AD). The goal...

  • Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. Bentué-Ferrer, Danièle; Tribut, Olivier; Polard, Elisabeth; Allain, Hervé; Bentué-Ferrer, Danièle; Allain, Hervé // CNS Drugs;2003, Vol. 17 Issue 13, p947 

    Cholinesterase inhibitors are the only pharmacological class indicated for the treatment of mild to moderate Alzheimer's disease. These drugs are also being used off label to treat severe cases of Alzheimer’s disease or vascular dementia and other disorders. The widespread use of...

  • Novartis' Exelon shown to reduces behavioral disturbances associated with Alzheimer's disease.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p6 

    Looks into the effect of cholinesterase inhibitor Exelon on the behavioral symptoms associated with Alzheimer's disease. Problems posed by behavioral symptoms in Alzheimer's disease patients; Effects of Exelon on neuropsychiatric and behavioral disturbances seen in patients with Alzheimer's...

  • Cognitive Pharmacotherapy of Alzheimer's Disease and Other Dementias. Herrmann, Nathan // Canadian Journal of Psychiatry;Oct2002, Vol. 47 Issue 8, p715 

    Objective: The objective of this paper is to review the randomized controlled trials (RCTs) on the pharmacotherapy of Alzheimer's disease and other dementias and to provide evidence-based recommendations for treatment of the cognitive impairment associated with these disorders. Method: A Medline...

  • Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Aalten, Pauline; Verhey, Frans R. J.; Boziki, Marina; Brugnolo, Andrea; Bullock, Roger; Byrne, Eleanor Jane; Camus, Vincent; Caputo, Miriam; Collins, Debby; De Deyn, Peter Paul; Elina, Kazi; Frisoni, Giovanni; Holmes, Clive; Hurt, Catherine; Marriott, Anna; Mecocci, Patrizia; Nobili, Flavio; Ousset, Pierre Jean; Reynish, Emma; Salmon, Eric // Dementia & Geriatric Cognitive Disorders;2007, Vol. 25 Issue 1, p1 

    Background/Aims: The aim of this study was to determine the consistency of neuropsychiatric subsyndromes of the Neuropsychiatric Inventory across several clinical and demographic subgroups (e.g. dementia subtypes, dementia severity, medication use, age and gender) in a large sample of...

  • Donepezil in Alzheimer’s Disease: What to Expect after 3 Years of Treatment in a Routine Clinical Setting. Wallin, Åsa K.; Andreasen, Niels; Eriksson, Sture; Båtsman, Stellan; Näsman, Birgitta; Ekdahl, Anne; Kilander, Lena; Grut, Mikael; Rydén, Marie; Wallin, Anders; Jonsson, Mikael; Olofsson, Hasse; Londos, Elisabeth; Wattmo, Carina; Jönhagen, Maria Eriksdotter; Minthon, Lennart // Dementia & Geriatric Cognitive Disorders;2007, Vol. 23 Issue 3, p150 

    Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer’s disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study...

  • Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice. López-Pousa, Secundino; Javier Arranz, Francisco // Patient Preference & Adherence;2013, Vol. 7, p47 

    Background: The aim of this study was to assess the sociodemographic and clinical characteristics of patients with Alzheimer's disease who switched from any oral cholinesterase inhibitor to rivastigmine patches. Methods: An observational, retrospective, multicenter study was conducted in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics